Silk sericin-based hydrogel, methods and uses thereof
11110206 · 2021-09-07
Assignee
Inventors
- Ana Leite De Almeida Monteiro De Oliveira (Matosinhos, PT)
- Sara Isabel Macedo Baptista Da Silva (Vila Nova de Gaia, PT)
- Sandra Cristina Ferreira Borges (Matosinhos, PT)
- Paulo Jorge Pereira Alves (Gondomar, PT)
Cpc classification
A61L15/64
HUMAN NECESSITIES
A61L2300/204
HUMAN NECESSITIES
A61L2300/232
HUMAN NECESSITIES
A61L2300/802
HUMAN NECESSITIES
C08J2389/00
CHEMISTRY; METALLURGY
A61L26/0047
HUMAN NECESSITIES
A61L15/60
HUMAN NECESSITIES
A61L2300/42
HUMAN NECESSITIES
A61L27/227
HUMAN NECESSITIES
A61L2300/102
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
International classification
A61L27/22
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
A61L15/64
HUMAN NECESSITIES
A61L26/00
HUMAN NECESSITIES
A61L15/60
HUMAN NECESSITIES
Abstract
The present disclosure relates to a novel sericin-based hydrogel wherein the silk sericin is enzymatically cross-linked for an improved treatment of wound healing, ischemic diseases or cardiovascular diseases, namely chronic wound healing, in particular diabetic wound.
Claims
1. A hydrogel comprising: at least 4% (w/v) of an enzymatically cross-linked silk sericin, wherein the silk sericin is enzymatically cross-linked by an enzyme complex selected from the group consisting of: horseradish peroxidase and hydrogen peroxide, laccase, transglutaminase, and mixtures thereof; wherein a cross-section of said hydrogel has pores with a diameter between 50-100 μm, and; wherein the hydrogel is suitable for medicinal applications, veterinary applications, cosmetic applications or as an in vitro model for cell culture studies.
2. The hydrogel of claim 1, wherein the hydrogel comprises at least 7.5% (w/v) of silk sericin.
3. The hydrogel of claim 1, comprising 4-20% (w/v) of an enzymatically cross-linked silk sericin.
4. The hydrogel of claim 1, comprising 6-7.5% (w/v) of an enzymatically cross-linked silk sericin.
5. The hydrogel of claim 1, wherein the silk sericin is enzymatically cross-linked by horseradish peroxidase and hydrogen peroxide for 10 seconds-5 minutes.
6. The hydrogel of claim 1, wherein the silk sericin is enzymatically cross-linked with 0.1-0.6% (w/v) of horseradish peroxidase and 0.15-0.4% (v/v) of hydrogen peroxide.
7. The hydrogel of claim 1, wherein the silk sericin has a molecular weight of 150-400 kDa.
8. The hydrogel of claim 1, wherein said hydrogel has an antioxidant activity of 0.03-0.05 eq [Asc. Ac.]g/L)/g.
9. The hydrogel of claim 1, further comprising a biological active agent, a therapeutic agent, an additive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier, and mixtures thereof.
10. The hydrogel of claim 9, wherein the additive is a surfactant selected from the following list: polysorbates, cationic molecules or polymers, and mixtures thereof.
11. The hydrogel of claim 9, wherein the additive is polysorbate 20, polysorbate 80 or poly-lysine.
12. The hydrogel of claim 9, wherein the biological active agent or the therapeutic agent is selected from the following list: antibiotic, coagulation agent, cell, stem cell, ligand, growth factor, platelet, and mixtures thereof.
13. The hydrogel of claim 12, wherein the antibiotic is vancomycin, streptomycin, ciprofloxacin, or mixtures thereof.
14. The hydrogel of claim 12, wherein the coagulation agent is thrombin or calcium.
15. The hydrogel of claim 1, wherein the hydrogel is transparent.
16. The hydrogel of claim 1, wherein the hydrogel is an injectable hydrogel or a topical hydrogel.
17. An adhesive or a patch comprising the hydrogel of claim 1.
18. A method for producing the hydrogel of claim 1, comprising the following steps: extracting silk sericin by immersing cocoons in water, at 100° C. for 40-60 min, in a ratio of 1-3% weight cocoons/volume of water; filtering the silk sericin; concentrating the silk sericin to at least 4% (w/v); preparing the hydrogel by adding 0.2% (w/v) of horseradish peroxidase, 0.3% (v/v) hydrogen peroxide and at least 4% (w/v) of silk sericin to water to form a mixture; and mixing the mixture for at least 10 seconds.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The following figures provide preferred embodiments for illustrating the description and should not be seen as limiting the scope of disclosure.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
DETAILED DESCRIPTION
(16) In an embodiment, Bombyx mori cocoons were supplied by the Portuguese Association of Parents and Friends of Mentally Disabled Citizens (APPACDM, Castelo Branco, Portugal). The other materials and reagents were purchased from Sigma-Aldrich (St Louis, Mo., USA) unless mentioned otherwise.
(17) In an embodiment, the preparation of silk solution and sericin-based hydrogels was conducted by sericin extraction by boiling, filtration and concentration to different weight ratios (i.e. 4, 7.5 and 7.8% (m/v)). Solutions were filtered and optimized at a final concentration of 7.5%. The hydrogel was prepared by adding different volumes and concentrations of HRP and hydrogen peroxide until gelation occurred (
(18) In an embodiment, the sericin quantification by dry weight was performed as follows: dry weights were determined by placing sample aliquots of sericin solution and hydrogel at 105° C. to a constant weight. In the end, the total solids were calculated according the equation:
(19)
(20) In equation, Wd refers to the dry weight of sample with container; Ww means wet weight of sample with container and We refers to the weight of container.
(21) In an embodiment, the sericin quantification by dry weight was determined and values of 0.67±0.05 and 7.54±0.50(%) were obtained for both, extracted sericin solution and final hydrogel formulation, respectively.
(22) In an embodiment, the microstructure evaluation and porosity analysis of the sericin-based hydrogel were performed by scanning electron microscopy (SEM). For this purpose, hydrogels were cast in moulds and immersed in liquid nitrogen to avoid the development of ice crystals, before freeze-drying. SEM was operated at low vacuum mode, using a spot size of 27-28 and a potential of 30 kV. All analyses were performed at room temperature, in particular at 20° C.
(23) In an embodiment, the morphology and microstructure of the sericin-based hydrogel were examined by SEM at different resolutions (
(24) In an embodiment, the structure and chemical analysis of sericin-based hydrogel were performed: sericin solution, HRP, hydrogen peroxide solution and the formed sericin-based hydrogels were further analysed by Infrared spectroscopy analysis in a Spectrum Series, Perkin Elmer FTIR spectrometer (ABB, Switzerland) equipped with attenuated total reflectance (ATR) sampling accessory (PIKE Technologies, USA), and a diamond/ZnSe crystal. All spectra were acquired using 16 scans and a 4 cm.sup.−1 resolution in the region of 4000-700 cm.sup.−1. In addition, baseline—point adjustment and spectra normalization was performed. PBS solution was used as background in the FTIR. All samples used were and run in triplicate, and the data presented were the average of the three measurements.
(25) In an embodiment, sericin-based hydrogel was successfully developed via HRP mediated cross-linking in physiological condition and presented transparent appearance, as showed in
(26) The ATR-FTIR spectra (
(27) In an embodiment, the differential scanning calorimetry analysis of the sericin-based hydrogel was conducted: thermograms were obtained using a DSC (DSC-60, Shimadzu, Columbia, USA). Hydrogels were prepared and kept at refrigerated conditions (4° C.) for 24 h, than 5.0 mg of the hydrogel were crimped in a standard aluminium pan and heated from 20° C. to 350° C. at a heating constant rate of 10° C./min under constant purging of nitrogen at 20 mL/min. All samples were run in triplicate and data presented were the average of the three measurements.
(28) In an embodiment, the similar thermal behavior was observed in both thermograms of sericin-based hydrogel and sericin solution (
(29) In an embodiment, mechanical tests of the sericin-based hydrogel was performed. The compression and perforation properties of hydrogels, were measured according to the Texture Analyser TXT plus from Stable Micro Systems (UK). The Exponent software was used for Ottawa cell with 6.5 mm holes, and 2 mm Dia cylinder stainless method. The hydrogels samples were prepared in a 24 wells plate (diameter of 1.5 cm and thickness of 3 mm). At least three disks of each hydrogel sample were analysed.
(30) Regarding the compression and perforation mechanical tests, sericin-based hydrogel were compared with well-described agar hydrogels at 1%. For the same distance (1.286 mm), and for 6 replicates of each formulation.
(31) This result clearly opens a new lack of opportunities for this novel hydrogel considering applications such as wound dressings, or other medical applications that requires resistant hydrogels, with good mechanical proprieties.
(32) In an embodiment, the rheology assessment of the sericin-based hydrogel was conducted. Oscillatory shear rheological tests were performed using a controlled stress rheometer (CS-50, Bohlin Instruments, Cranbury N.J., USA), with a cone-and-plate geometry (diameter 40 mm and angle 2°) fitted at 115 μm gap. The temperature of the bottom plate was controlled with a Peltier system. Immediately after preparation approximately 1.5 mL of the solution was transferred to the rheometer equilibrated at 25° C. Testing was then performed at low strain amplitude (1%) and low frequency (1 Hz), within the linear viscoelastic range—as assessed by stress and frequency sweep experiments, respectively. The gel development was assessed by measuring the storage modulus (G′) and the loss modulus (G″) through time sweep experiments (25° C., 1 Hz and 1%) carried out for approximately 1 h.
(33) In an embodiment, in vitro swelling ratio and degradation profile of the sericin-based hydrogel was performed. The prepared sericin-based hydrogel discs in 96 wells microplate, with 100 μL in each well, were used for the swelling and degradation study. The swelling ratios of the hydrogels were tested in both ultrapure water and PBS at 37° C. Each piece of hydrogel was placed in an eppendorf with 1 mL PBS or ultrapure water (0.55 μS/cm) prepared by a ultrapure water system (Millipore Q, Advantage A10, Germany), subsequently the samples were placed in a thermostatic water bath (Dubinoff bath BSD/D, Cambridgeshire, UK) at 37° C. The wet weight of the sample was measured at 1, 2, 4, 6, and 24 hours. Before weighting, surface liquid in the hydrogels were absorbed by tissue. The swelling ratio at each time point was calculated as following equation 1:
(34)
(35) In Equation 1, wt referred to the wet weight of the sample tested in different time point, and wd is the dry weight of the sample. It was assumed that the dry weight of each specimen was constant during the tested time-period.
(36)
(37) In an embodiment, for degradation assay hydrogels were tested in both PBS and PBS with Protease XIV from Streptomyces griseus at physiological concentration of 3.2 U/mg, according to previous works (30). Each piece of hydrogel was placed in an Eppendorf with 1 mL of each solution and then samples were placed in a thermostatic water bath (Dubinoff bath BSD/D, Cambridgeshire, UK) at 37° C. The wet weight of the sample was measured at 1, 2, 4, 6, 24, 48, 72, 96, 168, 240 and 312 hours. The degradation ratio at each time point was calculated as following equation 2:
(38)
(39) In equation 2, wi means the initial wet weight of the hydrogel, and wt is the wet weight tested at each point.
(40) In an embodiment, the pH responsiveness of the sericin-based hydrogels was performed. Sericin-based hydrogel discs in 96 wells microplate, with 100 μL in each well were immersed in 0.154 M NaCl solution (pH 7.4) (Panreac) at 37° C. overnight. The wet weights of the hydrogels were measured and then the hydrogels were immersed in 1 mL of NaCl solutions at different pH values (37° C.): 2.5, 5.5, 6.5 and 8.5. These pH values were selected according the pH values of healthy skin or injured skin. Healthy skin or acute wounds exhibit slightly acidic pH (pH values of 5.5-6.5) and chronic wounds have pH values higher than 7.4 caused by the microbial proliferation. Occasionally, the irregular vascularization of chronic wound is responsible for a heterogeneous dissemination of infection in the wound bed, causing drastic pH variations (31). The pH values were adjusted by addition of NaOH 1M (Merck, Darmstad, Germany) or HCl 1M (Merck, Darmstad, Germany). As control, the hydrogels were also immersed in methanol to undergo n-sheet conversion. After 2 h, 24 h, 96 h the wet weights of the hydrogels were recorded again after removing surface liquid. The wet weight variation was calculated as equation 3.
(41)
(42) In equation 3, wi means initial weight of the hydrogel after overnight immersion in 0.154 M sodium chloride solution, and wt refers to the wet weight tested during alternating immersion. The prepared discs were also immersed in methanol for 3 h to undergo 0 sheet conversion and then the opaque hydrogels were used as control for the response test as well as for swelling ratio and degradation tests.
(43) The hydrogels were submitted at different pH values similar to acute and chronic wounds (
(44) The
(45) The
(46) The results of the ionic strength responsive are presented in
(47) In an embodiment, the ionic strength responsiveness of the sericin-based hydrogel was performed. Sericin-based hydrogel discs in 96 wells microplate, with 100 μL in each well were used for the ionic strength response assay. Firstly, the hydrogels were immersed in 1 mL of PBS at 37° C. overnight and the wet weight of each hydrogel was measured. After this procedure, hydrogels were alternately placed in deionized water and PBS every 2 h during 8 h and the wet weights of the hydrogels were recorded. For the second part of the test, the hydrogels were immersed at 37° C. overnight in 1 mL 0.154M sodium chloride solution (pH 7.4, adjusted by 1.0 M NaOH) and the wet weight of each hydrogel was noted. Then, hydrogels were alternately immersed in 1 mL 2 M sodium chloride (pH 7.4) and 0.154 M sodium chloride solution (pH 7.4) every 2 h during 8 h. Before every change of solution, the wet weights of the hydrogels were measured. All the samples were maintained in the thermostatic water bath at 37° C. The wet weight variation ratio was calculated according to previous equation 3.
(48) In an embodiment, the UV assays were performed using UV-vis spectra were taken using a Shimadzu UV 3100 spectrometer equipped with an integrating sphere, covering a wavelength range between 250 and 850 nm (0.2 nm step-size, BaSO.sub.4 as the reference).
(49) In an embodiment, in order to investigate hydrophilic/hydrophobic nature of hydrogels, the water contact angle (WCA) was measured using an Optical Contact Angle (Dataphysics, Germany). WCA was performed using a sessile drop with a volume of 3 μL and measured with the OCA 20 software according Young-Laplace model.
(50) In an embodiment, sericin being more hydrophilic than silk fibroin (due to higher content of polar amino acids including serine, aspartic acid and glutamic acid), silk films become more hydrophilic with increasing sericin content, which results in lower contact angles (i.e. 33.23±4.48 degrees).
(51) In an embodiment, the antioxidant activity was determined, in particular the free radical-scavenging activity was determined by 2,2-azinobis-3-ethylbenzo thiazoline-6-sulphonic acid (ABTS) radical decolourization assay. The radical cation was produced by reacting ABTS with potassium persulfate. The antioxidant potential was measured according to the percentage of inhibition (PI), to be between 20% and 80%, to guarantee a linear response of the analytical method, after 6 min of reaction with 1 mL of diluted ABTS+ solution. Calibration curve was prepared with ascorbic acid in the range of 0.018-0.125 mg/mL and all the determinations accomplished in triplicate. In this assay, sericin solution after extraction and sericin-based hydrogel under physiological protease (3.5 U/mg) degradation after 24 h at 37° C., were used to evaluate the antioxidant potential. The total antioxidant capacity was expressed as mg ascorbic acid equivalent/mL.
(52) In an embodiment, the determination of the antioxidant capacity was performed by ABTS (2,2-azinobis (3-ethylbenzothiazoline-6-sulphonic) acid) diammonium salt test (SigmaAldrich, St. Louis, Mo., USA). The antioxidant potential was measured according to the percentage of inhibition (PI), to be between 20% and 80%, to guarantee a linear response of the analytical method, after 6 min of reaction with 1 mL of diluted ABTS•+ solution. The total antioxidant capacity was expressed in (eq [Asc. Ac.]g/L)/g extract. For this purpose sericin solution and sericin-based hydrogel were monitored to evaluate the antioxidant potential after sericin extraction, and after 24 h at 37° C. under physiological protease (3.5 U/mg) degradation.
(53) In an embodiment, the results have shown that even considered only a 20% of hydrogel degradation (according to the in vitro degradation profile, mentioned before) the sericin hydrogel showed antioxidant activity values of 0.053±0.002 (eq [Asc. Ac.]g/L)/g extract). In the other hand sericin solution showed antioxidant activity values of 0.032±0.008 (eq [Asc. Ac.]g/L)/g extract). There results clearly highlight the high antioxidant activity potential of sericin and of these novel crosslinked sericin hydrogels.
(54) In an embodiment, Staphylococcus aureus DSM 11729, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa, and Escherichia coli ATCC 25922 were obtained by collection culture of CBQF, Catholic University of Portugal. The isolates were growth aerobically on Nutrient agar (Merck, Darmstad, Germany) at 37° C. for 24 h.
(55) In an embodiment, the antimicrobial activity of sericin solution was determined using an inoculum of 0.5 MacFarland (1.5×10.sup.8 CFU/mL) of each bacteria. Muller-Hinton broth (Biokar) 180 μL with sericin solution with 0.67% was inoculated with 20 μL of each bacteria. Three controls were simultaneously assessed, one with 0.67% of sericin solution without inoculum, other with the Muller-Hinton broth with the inoculum and without the inoculum, each in triplicate. The absorbance was measured in a microplate reader (Fluostar Optima, BMG Laptech) at 620 nm during 24 h at 37° C.
(56) In an embodiment, the screening of antimicrobial activity of sericin-based hydrogels was performed by well diffusion assay. Plates of Nutrient Agar were seeded with an inoculum of 0.5 MacFarland (1.5×10.sup.8 CFU/mL) of each bacteria. Wells with a diameter of 4 mm were punctured into the plates and filled with 20 μL of hydrogel. Plates were incubated for 24 h at 37° C. The presence or absence of translucent halo zones around the wells were considered as positive or negative for antimicrobial activity, respectively. Control negative was made with Ringer's solution and assays were done in triplicate.
(57) In an embodiment, a mouse fibroblast cell line (L929), acquired from the European Collection of Cell Cultures (ECACC, United Kingdom) and used at passages 30-32. Cells were grown as monolayer cultures in Dulbecco's Modified Eagle's Medium (DMEM; Sigma Aldrich; Germany) supplemented with 10% fetal bovine serum (FBS; Biochrom, Germany) and 1% antibiotic-antimycotic liquid (Gibco, UK). The cells were incubated in a CO.sub.2 incubator under an atmosphere of 5% CO.sub.2 at 37° C., with medium change every two days. At confluence cells were detached from the culture flasks using TrypLE Express (1×) (Life Technologies, Carlsbad, Calif., USA), centrifuged, resuspended in the cell-culture medium, and seeded in the hydrogel at a density of (1.0×10.sup.4 cells/mL). The cell-seeded hydrogel were also incubated at 37° C., 5% CO.sub.2 and 95% humidity, for 1, 2, and 3 days. Tissue culture polystyrene (TCPS; Sarstedt) coverslips and SF membranes were used as control surfaces (33).
(58) In an embodiment, sericin-based hydrogel were prepared in aseptic conditions, in a sterile cabinet and used for the cell encapsulation. A warmed mixture (500 μL) was mixed with the cell pellet (cell suspension containing: 1.0×10.sup.4 cells/mL) and got a homogeneous cell suspension, and every 50 μL of the cell suspension was transferred into one piece of cover slips with 13 mm diameter (Sarstedt, Newton, N.C., USA) in a 24-well suspension cell culture plate. The plate was then placed into the CO.sub.2 incubator for around 10 minutes to allow the gelation. After the gel was formed, 1 mL (DMEM) alpha medium was supplemented into each well, and the medium was changed every two days. The Live/Dead of the incorporated cells was evaluated by Calcein AM and propidium iodide (Molecular Probes*; Life Technologies, Carlsbad, Calif., USA) staining, after culturing for 1, 2 and 3 days. For this assay, the hydrogels with cells were washed by PBS, and then immersed in 1 mL PBS supplemented with 1 μg Calcein AM and 2 μg propidium iodide for 30 minutes. The samples were observed in a transmitted and reflected light microscope (Axio Imager Z1m, Zeiss, Jena, Germany) after washing by PBS (34). The effect of hydrogels on cell viability was measured at selected concentrations using the methylthiazolyldiphenyl-tetrazolium bromide conversion (MTT) assay at 1, 2 and 3 days. For this assay, 100 μL MTT (5 mg/mL in PBS) working solution was added into each well, followed by incubated for 2 hours. The absorbance of 50 μL supernatant from each well was read in a microplate reader (Fluostar Optima, BMG Laptech) at 570 and 690 nm. Hydrogels without cells were used as control. Each treatment was tested in four individual wells. The negative control used, was also DMSO. The plates were shaken on an orbital shaker to solubilize the crystals of formazan. The hydrogels encapsulated with cells were frozen and then lyophilized, after culturing for 3 days, respectively. The morphology of the hydrogels was observed by scanning electron microscopy (SEM). (JEOL-5600 Lv microscope, Japan) observation, the samples after coated with a layer of Au/Pd SC502314B in an evaporator coater (E6700, Quorum Technologies, East Grinstead, UK).
(59) In an embodiment, the MTT test demonstrates biocompatibility and capacity for cell encapsulation of the hydrogel disclosed in the present subject matter.
(60) In an embodiment, the hemocompatibility studies demonstrate excellent blood compatibility, exhibiting low hemolysis ratio, anti-coagulant and anti-thrombogenic activities of the hydrogel disclosed in the present subject matter.
(61) Throughout the description and claims the word “comprise” and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Additional objectives, advantages and features of the solution will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the solution.
(62) The term “comprising” whenever used in this document is intended to indicate the presence of stated features, integers, steps, components, but not to preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
(63) It will be appreciated by those of ordinary skill in the art that unless otherwise indicated herein, the particular sequence of steps described is illustrative only and can be varied without departing from the disclosure. Thus, unless otherwise stated the steps described are so unordered meaning that, when possible, the steps can be performed in any convenient or desirable order.
(64) The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof.
(65) The above-described embodiments are combinable.
(66) The following claims further set out particular embodiments of the disclosure.
(67) The following references, should be considered herewith incorporated in their entirety: 1. Boateng J, Burgos-Amador R, Okeke O, Pawar H. Composite alginate and gelatin based bio-polymeric wafers containing silver sulfadiazine for wound healing. International Journal of Biological Macromolecules. 2015; 79:63-71. 2. Jin S G, Yousaf A M, Kim K S, Kim D W, Kim D S, Kim J K, et al. Influence of hydrophilic polymers on functional properties and wound healing efficacy of hydrocolloid based wound dressings. International Journal of Pharmaceutics. 2016; 501 (1-2): 160-6. 3. Phillips C J, Humphreys I, Fletcher J, Harding K, Chamberlain G, Macey 4 S. Estimating the costs associated with the management of patients with chronic wounds using linked routine data. International Wound Journal. 2015; ISSN 1742-4801. 4. Hurd T. Understanding the financial benefits of optimising wellbeing in patients living with a wound. Wounds International. 2013; 4(2):13-7. 5. Kathleen M. Understanding and overcoming the challenges of effective case management for patients with chronic wounds. The Case Manager. 2005; 16(2):62-7. 6. Petrie N C, Yao F, Erickson E. Therapy in wound healing. Surgical Clinics of North America. 2003; 83:194-9. 7. Sen C K, Gordillo G M, Roy 5, Kirsner R, Lambert L, Hunt T K, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair and Regeneration. 2009; 17:763-71. 8. Sivaranjani V, Philominathan P. Synthesize of Titanium dioxide nanoparticles using Moringa oleifera leaves and evaluation of wound healing activity. Wound Medicine. 2016; 12:1-5. 9. Frykberg R G, Armstrong D G, Giurini J, Edwards A, Kravette M, Kravitz 5, et al. Diabetic foot disorders: a clinical practice guideline. Journal of Foot and Ankle Surgery. 2000; 39 (5 Suppl): S1-60. 10. Macdonald J M, Geyer M J. Wound and lymphoedema management. World Health Organization. 2010; WHO/HTM/NTD/GBUI/2010: ISBN 978 92 4 159913 9. 11. Dhivya S, Padma W, Santhini E. Wound dressings—a review. BioMedicine. 2015; 5(4):22. 12. Gainza G, Villullas S, Pedraz J L, Hernandez R M, Igartua M. Advances in drug delivery systems (DDSs) to release growth factors for wound healing and skin regeneration. Nanomedicine: nanotechnology, biology, and medicine. 2015; 11(6):1551-73. 13. Mahmoud A A, Salama A H. Norfloxacin-loaded collagen/chitosan scaffolds for skin reconstruction: Preparation, evaluation and in-vivo wound healing assessment. European Journal of Pharmaceutical Sciences. 2016; 83:155-65. 14. Catanzano O, D'Esposito V, Acierno 5, Ambrosio M R, De Caro C, Avagliano C, et al. Alginate-hyaluronan composite hydrogels accelerate wound healing process. Carbohydrate Polymers. 2015; 131:407-14. 15. Fan L, Yang H, Yang J, Peng M, Hu J. Preparation and characterization of chitosan/gelatin/PVA hydrogel for wound dressings. Carbohydrate Polymers. 2016; 146:427-34. 16. Atala A. Regenerative medicine strategies. Journal of Pediatric Surgery. 2012; 47:17-28. 17. Aramwit P, Siritientong T, Srichana T. Potential applications of silk sericin, a natural protein from textile industry by-products. Waste Management & Research. 2011; 30(3):217-24. 18. Nishida A, Yamada M, Kanazawa T, Takashima Y, Ouchi K, Okada H. Sustained-release of protein from biodegradable sericin film, gel and spong. International Journal of Pharmaceutics. 2011; 407:44-52. 19. Chlapanidas T, Farago S, Lucconi G, Perteghella 5, Galuzzi M, Mantelli M, et al. Sericins exhibit ROS-scavenging, anti-tyrosinase, anti-elastase, and in vitro immunomodulatory activities. Int J Biol Macromol. 2013; 58:47-56. 20. Kaur J, Rajkhowa R, Tsuzuki T, Millington K, Zhang J, Wang X. Photoprotection by silk cocoons. Biomacromolecules. 2013; 14(10):3660-7. 21. Berardesca E, Ardigo M, Cameli N, Mariano M, Agozzino M, Matts P J. Randomized, double-blinded, vehicle-controlled, split-face study to evaluate the effects of topical application of a Gold Silk Sericin/Niacinamide/Signaline complex on biophysical parameters related to skin ageing. International journal of cosmetic science. 2015; 37(6):606-12. 22. Ohnishi K, Murakami M, Morikawa M, Yamaguchi A. Effect of the silk protein sericin on cryopreserved rat islets. Journal of hepato-biliary-pancreatic sciences. 2012; 19(4):354-60. 23. Morikawa M, Kimura T, Murakami M, Katayama K, Terada S, Yamaguchi A. Rat islet culture in serum-free medium containing silk protein sericin. Journal of hepato-biliary-pancreatic surgery. 2009; 16(2):223-8. 24. Wang Z, Zhang Y, Zhang J, Huang L, Liu J, Li Y, et al. Exploring natural silk protein sericin for regenerative medicine: an injectable, photoluminescent, cell-adhesive 3D hydrogel. Scientific Reports. 2014; 4:7064:1-11. 25. Song Y, Zhang C, Zhang J, Sun N, Huang K, Li H, et al. An injectable silk sericin hydrogel promotes cardiac functional recovery after ischemic myocardial infarction. Acta Biomaterialia. 26. Chen L, Hu J, Ran J, Shen X, Tong H. A novel nanocomposite for bone tissue engineering based on chitosan-silk sericin/hydroxyapatite: biomimetic synthesis and its cytocompatibility. RSC Advances. 2015; 5(69):56410-22. 27. Kundu B, Kundu S C. Silk sericin/polyacrylamide in situ forming hydrogels for dermal reconstruction. Biomaterials. 2012; 33(30):7456-67. 28. Khampieng T, Aramwit P, Supaphol P. Silk sericin loaded alginate nanoparticles: Preparation and anti-inflammatory efficacy. International Journal of Biological Macromolecules. 2015; 80:636-43. 29. Shi L, Yang N, Zhang H, Chen L, Tao L, Wei Y, et al. A novel poly(γ-glutamic acid)/silk-sericin hydrogel for wound dressing: Synthesis, characterization and biological evaluation. Materials Science and Engineering: C. 2015; 48:533-40. 30. Almeida L R, Martins A R, Fernandes E M, Oliveira M B, Correlo V M, Pashkuleva I, et al. New biotextiles for tissue engineering: Development, characterization and in vitro cellular viability. Acta Biomaterialia. 2013; 9:8167-81. 31. Rahimi R, Ochoa M, Parupudi T, Zhao X, Yazdi I K, Dokmeci M R, et al. A low-cost flexible pH sensor array for wound assessment. Sensors and Actuators B: Chemical. 2016; 229:609-17. 32. Ramos Ó L, Reinas I, Silva S I, Fernandes J C, Cerqueira M A, Pereira R N, et al. Effect of whey protein purity and glycerol content upon physical properties of edible films manufactured therefrom. Food Hydrocolloids. 2013; 30(1):110-22. 33. Ribeiro V P, Almeida L R, Martins A R, Pashkuleva I, Marques A P, Ribeiro A S, et al. Influence of different surface modification treatments on silk biotextilesfor tissue engineering applications. Journal of Biomedical Material Research Part B.00B: 000-000. 34. Yan L-P, Silva-Correia J, Oliveira M B, Vilela C, Pereira H, Sousa R A, et al. Bilayered silk/silk-nanoCaP scaffolds for osteochondral tissue engineering: In vitro and in vivo assessment of biological performance Acta Biomaterialia. 2015; 12:227-41.